UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

☒	ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the fiscal year ended September 30, 2021
	For the fiscal year ended September 30, 2022
☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
	For the transition period from to __________
	For the period from to __________
	Commission File Number: 333-146834

Regenicin, Inc.

(Exact name of registrant as specified in its charter)

Nevada	27-3083341
Wyoming	27-3083341
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
10 High Court, Little Falls, NJ	07424
(Address of principal executive offices)	(Zip Code)
Registrant’s telephone number: 973 557 8914

Securities registered under Section 12(b) of the Exchange Act
Title of each class	Name of each exchange on which registered
None	not applicable

Securities registered under Section 12(g) of the Exchange Act:
Title of each class
None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes ☒ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐Yes ☒ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☐Yes ☒ No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Non-accelerated Filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐Yes ☒No

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed ~~second~~ fiscal quarter: Approximately $31,~~069~~534,~~661~~830 as of ~~March~~December 31, ~~2021~~2022.

~~State~~Indicate the number of shares outstanding of each of the ~~issuer~~registrant’s classes of common stock, as of the latest practicable date: 153,483,050 as of December 31, ~~2021~~2022.

NOTICE: THIS 10K FILING DOES NOT CONTAIN ~~FINANCIAL~~ FINANCIAL OR OTHER INFORMATION WHICH HAS BEEN AUDITED OR REVIEWED BY OUR INDEPENDENT PUBLIC ACCOUNTING FIRM FOR REASONS SPECIFIED HEREIN. WE INTEND TO SUPPLEMENT THIS FILING, AT A CURRENTLY UNKNOWN LATER DATE, WITH SUCH AUDITED FINANCIAL INFORMATION, IF AND WHEN SUCH AN AUDIT CAN BE OBTAINED.

Table of Contents

TABLE OF CONTENTS

		Page
PART I
Item 1.	Business	3
Item 1A.	Risk Factors	5
Item 1B.	Unresolved Staff Comments	6
Item 2.	Properties	6
Item 3.	Legal Proceedings	6
Item 4.	Mine Safety Disclosures	6
PART II
Item 5.	Market for Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities	7
Item 6.	Selected Financial Data	9
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	11
Item 8.	Financial Statements and Supplementary Data	11
Item 9.	Changes In and Disagreements With Accountants on Accounting and Financial Disclosure	12
Item 9A.	Controls and Procedures	12
Item 9B.	Other Information	13
PART III
Item 10.	Directors, Executive Officers and Corporate Governance	14
Item 11.	Executive Compensation	16
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	17
Item 13.	Certain Relationships and Related Transactions, and Director Independence	18
Item 14.	Principal Accountant Fees and Services	18
	PART IV
Item 15.	Exhibits, Financial Statement Schedules	19

Table of Contents

PART I

Item 1. Business

Overview of key events of the year ended September 30, ~~2021~~ 2022

During ~~2020~~2021-2122, ~~the~~we ~~Company~~ continued to ~~position~~work on obtaining ~~its~~funding ~~product,~~in ~~NovaDerm®,~~order to ~~enter~~start clinical trials toand gain FDA product approval for our product, NovaDerm®. Having secured ~~Orphan~~an Orphan Drug Designation as a biologic for ~~NovaDerm®~~this product, we ~~complied~~continued to comply with the FDA annual reporting requirements.

~~During~~To ~~2020,~~avoid the ~~risk~~introduction of ~~introducing~~ pathogens when ~~using~~ using materials from animals to produce drugs, devices, and biologics, ~~has increased awareness of the safety issues.~~ NovaDerm® and future Regenicin products all use tracible and pure animal sourced materials ~~like collagen to produce the life-saving products~~. We have worked with ~~our~~ ~~collagen supplier and~~ the FDA to ensure we are meeting ~~the~~federal expectations ~~for~~in ~~traceability~~this ~~and~~regard ~~purity~~during of the ~~FDA for NovaDerm®~~ production process.

We ~~estimated~~estimate that the completion of the IND and the clinical trials ~~would~~will take ~~approximately~~at ~~12-~~least 18 months and cost ~~approximately~~in ~~$6.9~~excess ~~million~~of ~~once~~$7 ~~initial funding is in place~~million. In addition to the completion of the IND, the only other significant gating item to ~~entering~~enter ~~the~~ clinical trials ishas been finding funding for this process.

~~Two~~Subsequent ~~board~~to ~~positions~~the ~~remain~~end ~~open~~of ~~anticipating~~this ~~requests~~fiscal year, we began selling materials and rights to our NovaDerm® product to individuals through a new Nevada series LLC we set up, NovaDerm Product Package LLC, as more fully described in the next section entitled ‘Our Business Moving Forward In 2023’. These rights and material sales generated a substantial amount of ~~Board~~funding ~~representation~~which ~~from~~we ~~potential~~believe ~~investors~~will provide us enough capital to complete the NovaDerm IND and allow us to proceed with the Clinical Trials of our NovaDerm® product. No assurance can be given, however, as to the results of such Clinical Trials, any future FDA approval, or our ability to complete and offer our NovaDerm® product commercially in the future.

~~Our~~Three ~~Business~~board ~~Moving~~positions ~~Forward~~remain Inopen ~~2022~~ on our Board of Directors.

~~Our~~Importantly, ~~major~~we ~~objective~~are ~~for~~filing ~~2022~~this ~~remains~~annual toreport ~~secure the~~without ~~required~~our ~~funding~~auditor’s toreview ~~finalize~~or ~~some~~any ~~additional~~audit ~~requirements~~ of ~~the~~our ~~IND~~financial ~~application~~information ~~and~~or ~~begin~~this ~~the clinical trials~~report. ItOur isreason ~~estimated~~for ~~that the~~doing ~~cost~~this tois ~~finalize~~that ~~the~~we ~~IND~~are ~~will~~still benegotiating with ~~approximately~~our ~~1.9~~potential ~~million~~auditors ~~dollars,~~for ~~and~~ the ~~cost~~completion ~~to complete Phase 1/2~~ of ~~the~~an ~~clinical~~audit ~~trial~~and ~~will be~~review ~~approximately~~of ~~5.0 million dollars. As previously reported,~~ our ~~goal~~unaudited inpast ~~obtaining~~years ~~this~~reports ~~funding~~prior ~~has been~~ to ~~minimize~~obtaining ~~shareholders'~~an ~~dilution~~audit asof ~~much~~this ascurrent ~~possible~~10K filing. ~~Consequently~~Instead, we ~~are~~have ~~primarily~~provided ~~pursuing~~herein ~~financing~~information ~~through~~as ~~the~~typically ~~issuance~~presented ofin aour ~~debt~~10K ~~instrument~~annual report, ~~international~~including ~~licensing~~financial ~~agreements and government grants~~information, which ~~have~~has not been ~~greatly~~reviewed ~~restricted~~or toaudited ~~Covid-19~~by ~~related~~any ~~grants~~independent outside source.

We ~~will~~intend, ~~continue~~if toand ~~work~~when ~~with~~able, ~~potential~~to ~~investors in~~file ~~order~~an amendment to ~~pursue~~this ~~the~~10K ~~necessary~~filing ~~funding~~with ~~based~~such onaudited ~~our~~information. ~~stated~~We ~~objectives.~~are Itunaware ~~has~~at ~~taken~~this ~~longer~~time towhen ~~raise~~we will obtain the ~~funds~~necessary ~~than~~audit ~~originally~~of ~~estimated;~~the current and past filings; however, we ~~remain~~will ~~confident~~continue ~~that~~to ~~our~~provide ~~goal~~current isinformation ~~achievable.~~to Ininvestors ~~the~~and ~~interim,~~ the ~~officers~~public ~~and~~when ~~related~~we ~~parties~~are ~~intend~~able tothrough ~~continue~~either ~~to fund~~ our EDGAR ~~essential~~filings ~~operating~~and/or ~~costs~~through aspostings ~~they~~on ~~have~~our ~~in the past~~website.

~~In preparation of the IND application, we will continue to develop the testing suggested by the FDA during the Pre-IND meeting.~~ Our ~~scaffold~~Business ~~supplier~~Moving ~~continues~~Forward toIn introduce the FDA suggested testing on collagen processing which addresses Bovine Closed Herd requirements for the tighter safety and traceability of the collagen scaffolds used to produce NovaDerm®. Our scaffold supplier is close to entering a contract for ASTM-F2212 testing of Type I collagen. We continue discussions and evaluation of possible clinical trial sites for NovaDerm®. Our discussions have confirmed that patient recruitment and enrollment should be faster and less complicated than other clinical trials because of our Orphan Designation and the surgical protocol will be similar to the grafting procedures currently in use at those facilities. NovaDerm® should thus require minimal physician training and documentation to complete the clinical trial, when and if conducted.2023

~~Subject~~Subsequent to ~~funding,~~ the ~~initial~~end ~~trials~~of ~~are~~this ~~planned~~fiscal year, in October to2022, ~~begin~~we ~~with~~set up a ~~total~~new ofNevada ~~ten~~Series ~~subjects~~LLC called NovaDerm Product Package, LLC (“NPP LLC”). During November and anDecember ~~Initial~~2022, consistent ~~Data~~with ~~Safety~~Nevada ~~Monitoring~~law ~~Board~~governing this Master Series LLC, we then establish twenty-five (~~DSMB~~25), ~~review~~individual ofseries ~~safety~~LLCs, onidentifying ~~the~~each with ~~first~~a ~~three~~series ~~subjects once~~letter ~~they~~of ~~have~~A ~~reached~~through 6T ~~months~~or ~~follow-up.~~AA Wethrough doEE. ~~not~~Thus, ~~intend~~each toof ~~interrupt~~these ~~our~~sub-entities ~~trial~~were ~~waiting~~named ~~for~~NovaDerm ~~the~~Product ~~DSMB~~Package ~~report.~~Series ~~Our~~A, ~~management’s~~LLC ~~approach~~through isSeries toT, ~~set~~LLC, upand ~~the~~then ~~trials~~Series soAA as to ~~allow~~Series ~~for~~EE, aLLC ~~seamless~~(or ~~transition~~NPP-A ~~into~~through ~~commercial~~NPP-T ~~production~~and ~~upon~~NPP-AA ~~approval~~through NPP-EE for short).

WeInto ~~have~~each ~~arranged~~of ~~for~~these ~~sufficient~~twenty-five ~~Bovine~~individual ~~Closed~~Series ~~Herd~~LLCs, we contributed the right and exclusive ownership to a certain amount of the bovine hides and corium we currently own and use as key materials in the preparation of our NovaDerm® product, as well as the right to ~~produce~~designate: ~~sufficient~~(a) ~~collagen~~the ~~scaffolds~~specific patient cultured skin to ~~meet~~be ~~our~~prepared from ~~needs~~these ~~for~~materials; (b) the ~~clinical~~amount ~~trials~~of ifthis ~~they~~cultured skin to be prepared up to a designated amount and (c) the medical facility to receive the fully prepared and processed NovaDerm® cultured skin from these materials (these materials and combined designation rights are collectively ~~conducted~~referred to herein as the “NovaDerm® Product Rights”). For NPP-A through NPP-T and NPP-AA through NPP-CC we designated 33,333 cm2 of these NovaDerm® Product Rights. For NPP-DD we designated 30,625 cm2 of NovaDerm® Product Rights and for NPP-EE we designated 28,783 cm2 of NovaDerm® Product Rights. Each contribution of each of the NovaDerm® Product Rights was provided in exchange for 100 membership interests in the Series LLC which represented 100% of all membership interests issued.

While we retain possession of the materials transferred in each Series LLC contribution, we have a continuing obligation to segregated and manage those materials as well as to prepare the NovaDerm® cultured skin product as designated by each Series LLC holder or their designate. The identified materials are currently set apart from other such materials and are being held by us pending the identification of the patient and medical facility as instructed by each NovaDerm® Product Rights holder. Notwithstanding this retention of possession by us, the ownership and legal title to the materials are retained and fully vested in the individual Series LLC or its designate.

Table of Contents

The above-described transfers of membership interests in the Series LLCs generated a substantial amount of cash which we are obligated to use for the completion of our NovaDerm IND and the administration of our product clinical trials. No assurance, however, can be given as to the success or failure of such IND or clinical trials, or as to any future FDA decisions made following these trials.

Our major objective for 2023 remains to complete the requirements of our NovaDerm IND application and begin our clinical trials. It is estimated that the cost to finalize the IND will be approximately $1.9 million dollars, and the cost to complete Phase 1/2 of the clinical trial will be approximately 5.0 million dollars. There can be no assurance that we will be able to complete these tasks for these estimated amounts or that we will be successful in the proving out our NovaDerm® Product in this process. Indeed, clinic trials are notoriously difficult and expensive and are likely to result in additional unplanned costs and a denial of FDA approval.

As previously reported, our goal in obtaining funding for this process has been to minimize shareholders' dilution as much as possible. We believe the manner in which we structured our sales of NovaDerm® Product Rights has successfully achieved this objective. We will continue to work with potential investors in order to pursue other necessary funding based on our stated objective of successfully completing our planned clinical trials and obtaining FDA approval for the commercial sale of our NovaDerm® Product. It has taken longer to raise the funds than originally estimated; however, we remain hopeful that our goal is now achievable.

In the preparation of the IND application, we will continue to develop the testing suggested by the FDA during our Pre-IND meeting. Our scaffold supplier continues to perform the FDA suggested testing on collagen processing which addresses Bovine Closed Herd requirements for the enhanced safety and traceability of the collagen scaffolds used to produce NovaDerm^®. We will be entering into discussions and evaluation of possible clinical trial sites for NovaDerm^® as we proceed through the FDA approval process. Our discussions so far have confirmed that patient recruitment and enrollment should be faster and less complicated than other clinical trials because of our Orphan Designation and the fact that the surgical protocol will be similar to the grafting procedures currently in use at most facilities. NovaDerm^® should thus require minimal physician training and documentation to complete the clinical trial, when and if conducted.

We are in the process of preparing a detailed plan and timeline for the filing of our IND and commencement of clinical trials and will provide this information when complete and approved by our board of directors. Our initial trials are planned to begin with a total of ten subjects and an Initial Data Safety Monitoring Board, (DSMB), review of safety on the first three subjects once they have reached 6 months follow-up. We do not intend to interrupt our trial waiting for the DSMB report. Our management’s approach is to set up the trials so as to allow for a seamless transition into commercial production upon approval. We have arranged for sufficient Bovine Closed Herd corium to produce sufficient collagen scaffolds to meet our needs for the clinical trials once the IND is approved.

Our First Product Candidate NovaDerm^®

Our first cultured skin substitute product candidate, NovaDerm^®, is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient’s own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. Clinically, we expect our Cultured Skin substitute self-to-self skin graft product will perform the same as split thickness allograft skin. Our Autologous cultured skin substitute should not be rejected by the immune system of the patient, unlike porcine or cadaver cellular grafts. Immune system rejection is a serious concern in Xeno-transplant procedures which have a cellular component. The use of our cultured skin substitute should not require any specialized physician training because it is applied the same as in a standard split thickness allograft procedure.

NovaDerm® does not require the large harvest areas that are required when performing split thickness allograft procedures. NovaDerm® is designed to need only a small area of harvest material to cover the wound. ~~Where~~This is a marked improvement over split thickness allograft skin which can be stretched only 2 to 4 times, ~~NovaDerm® can~~its ~~expand~~original ~~the~~ coverage ~~100 to 400 times, greatly reducing scarring from harvesting~~area. ~~There~~This ~~are~~results ~~limits~~in tolimitations on how much burned area can be covered with ~~the~~this ~~current split thickness allograft~~ procedure. When a patient has more than 50% of their body with full thickness burns , there is simply not enough harvest area available to cover the burned area. soAs a result, the same area harvested must be allowed to grow back ~~the~~to get enough replacement skin, ~~before~~allowing itfor ~~can~~a behigh ~~harvested~~risk of ~~the~~infection ~~second~~and oreven ~~third~~mortality. ~~time,~~NovaDerm® ~~allowing~~is expected to ~~wound~~expand ~~area~~100 ~~open~~to ~~with~~400 ~~high~~times ~~risk~~in ofcoverage, ~~infection~~greatly ~~and~~reducing ~~even~~this ~~mortality~~problem as well as scarring caused by harvesting.

Clinically speaking, a product designed to treat a a life-threatening condition must be available for the patient when needed. Our Culture skin substitute is being developed to be ready to to apply to the patient ~~when~~within the ~~patient~~first ismonth ~~ready~~of ~~for~~admission ~~grafting,~~to ~~within~~ the ~~first~~hospital, ~~month~~when of the patient ~~being~~is ~~admitted~~ready tofor ~~the hospital~~grafting. Patients with serious burn injuries may not be in a condition to be grafted on a predefined schedule made more than a month in advance. Therefore, in order to accommodate the patient’s needs, we are striving to ensure that our cultured skin substitute will have an adequate shelf life and manufacturing schedule to ensure it is available whether the patient needs it the first month, or any day after, until the patient’s wound is completely covered and closed. We intend to provide ~~the~~a patient with enough NovaDerm® to meet the patients’ needs in a single lot of material with adequate shelf life to be available when the patient is ready. With ~~our~~ an extended shelf life and enough material in the first shipment, ~~the~~a physician may perform a second grafting 5 orto ~~ten~~10 days post the first grafting ~~period~~ 1period.

~~Our~~At ~~second~~this product is anticipated to be TempaDerm®. TempaDerm® uses cells obtained from human donors to develop banks of cryo-preserved (frozen) cells and cultured skin substitute to provide a continuous supply of non-allogenic skin substitutes to treat much smaller wound areas on patientstime, ~~such~~we asfirst ~~ulcers.~~plan ~~This product is expected~~ to ~~have~~seek ~~applications~~FDA inapproval ~~the treatment of chronic skin wounds such as diabetic ulcers, decubitus ulcers and venous stasis ulcers. This product is also expected to be similar to our burn indication product, except~~ for ~~the indications, and it will not~~ ~~depend~~burns ~~totally~~as onan ~~autologous~~Orphan ~~cells.~~Biologic InProduct ~~fact, it may be possible~~ to ~~use~~establish ~~the~~significant ~~excess~~safety ~~cultured~~data ~~skin that was originally produced for use on the patient that donated the cells used to grow the skin. Hopefully, TempaDerm® will be able to take this original cultured skin~~ and ~~use~~then itseek onBiological ~~someone~~License ~~other than the original donor~~Approval. As currently planned, TempaDerm® has the possibility of using banked cells, or even frozen cultured skin substitutes, to carry inventory to satisfy unknown needs or large volumes to meet the demands created in large scale disasters. Because of our focus to date on NovaDerm®, we have taken only limited steps toward the development of TempaDerm®. We may also decellularize TempaDerm® or NovaDerm® to make collagen wound coverings containing all the natural growth promoters found in skin.

WeOur ~~believe~~second ~~this~~product ~~technology~~is anticipated ~~has~~to ~~many~~be ~~different~~TempaDerm® . TempaDerm® uses cells ~~beyond~~obtained ~~the~~from ~~burn~~human ~~indication.~~donors ~~The~~to ~~other~~develop ~~uses~~banks ~~may~~of ~~include~~cryo-preserved ~~chronic~~(frozen) ~~wounds,~~cells ~~reconstructive~~and ~~surgery,~~cultured ~~other~~skin ~~complex~~substitutes ~~organs~~to ~~and~~provide ~~tissues.~~a ~~Some~~continuous supply of ~~the~~non-allogenic ~~individual~~skin ~~components~~substitutes ofto ~~our~~treat ~~planned~~much ~~cultured~~smaller ~~skin~~wound ~~substitute~~areas ~~technology~~on patients, such as ulcers. This product is expected to behave ~~developed~~applications in ~~for~~the ~~devices,~~treatment of chronic skin wounds such as ~~tendon wraps~~diabetic ~~made~~ulcers, ofdecubitus ~~collagen~~ulcers orand ~~collagen~~venous ~~temporary~~stasis ~~coverings~~ulcers. ofThis ~~large~~product ~~area~~is ~~wounds~~expected to be ~~protect~~similar ~~the~~to ~~patients~~our ~~from~~burn ~~infections~~indication ~~while~~product, ~~waiting~~except for the ~~permanent~~indications, ~~skin~~and ~~substitute~~it will not depend totally on autologous cells. ~~The~~In ~~collagen~~fact, ~~technology~~it may ~~used~~be ~~for~~possible to use the excess cultured skin ~~substitutes,~~that aswas ~~designed,~~originally isproduced ~~expected~~for use on the patient that donated the cells to grow the skin. Potentially, TempaDerm® will be ~~used~~able ~~for~~to ~~many different~~take ~~applications~~this inoriginal ~~wound~~cultured ~~healing~~skin and ~~stem~~use ~~cell~~it ~~technology~~on ~~and~~someone ~~even~~other ~~drug~~than ~~delivery~~the ~~systems~~original donor.

WeAs ~~could~~currently ~~pursue~~planned, ~~any~~TempaDerm® orhas the ~~all~~possibility of ~~the~~using ~~indications~~banked ~~simultaneously if~~cells, ~~financing~~or ~~permitted~~even frozen cultured skin substitutes, ~~but~~to ~~for~~carry ~~now~~inventory weto ~~will~~satisfy ~~seek~~unknown ~~approval~~needs ~~for~~or ~~burns~~large volumes ~~first~~to asmeet anthe ~~Orphan~~demands ~~Biologic~~created ~~Product~~in large scale disasters. Because of our focus to ~~establish~~date ~~significant~~on ~~safety~~NovaDerm®, we have taken ~~data~~only ~~and~~limited ~~then~~steps ~~Biological~~toward ~~License~~the ~~Approval~~development of TempaDerm®. We may also decellularize TempaDerm® or NovaDerm® to make collagen wound coverings containing all the natural growth promoters found in skin.

We believe this technology has many different uses beyond the burn indication. The other uses may include chronic wounds, reconstructive surgery, and potentially other complex organs and tissues. Some of the individual components of our planned cultured skin substitute technology is expected to be developed for devices, such as tendon wraps made of collagen or collagen temporary coverings of large area wounds to protect the patients from infections while waiting for a permanent skin substitute. The collagen technology used for cultured skin substitutes, as designed, is expected to be used for many different applications in wound healing and stem cell technology and even drug delivery systems.

Table of Contents

Competition

Several companies have developed or are developing products that propose to approach the markets described above. There is only one other Autologous Cultured Skin Substitute for severe burns designated as an orphan product candidate, the original Cutanogen’s PermaDerm. ~~Recently~~This ~~this~~ product was licensed by Amarantus to Emerald Organic Products, but, to our knowledge, it has not be approved by the FDA or gone through any clinical trials .

WeIn any case, we believe our ~~products~~product tois be superior in ~~design~~ design and function and, thus, ~~provide~~provides significant advantages over ~~the~~this competitor. The advantages of our cultured skin substitute include: (a) simultaneous delivery of ~~Autologous~~autologous epidermal keratinocytes and fibroblasts organized with a unique collagen base, is(b) it can be produced and ready for ~~the~~ patient use in 21 to 28 days, and (c) it has a shelf life of up to 2 weeks once produced.

Government Regulation

The Pediatric Medical Device Safety and Improvement Act of 2007 (Public Law 110-85) provides that Orphan Product applications for pediatric use only, or for use in both pediatric and adult patients, that are approved on or after September 27, 2007, are assigned an annual distribution number (ADN) and may be sold for profit (subject to the upper limit of the ADN). In addition, once a product receives an Orphan BLA, the developer of the product receives up to seven years market exclusivity for a specific indication following the product’s approval by the FDA.

Unrestricted sales of our cultured skin substitute will ~~require~~not be permitted until we have obtained full FDA approval after data for safety and efficacy are collected from aan ~~clinical~~approved clinical study. Once an IND is submitted, we expect enrollment and treatment to require a full one-year of evaluation on each patient before our product can be fully assessed for human use. The final 3 months of the evaluation is expected to be only a monitoring period. After collection of data from the clinical trial and submission to the FDA, six months is typically planned for the FDA’s review and comments before a decision inwill be reached on whether or not to approve our product and what limitations on its use may be placed. Because of our Orphan Designation, this review time is expected to be reduced significantly.

Intellectual Property

In 2016, we received a registered trademark for NovaDerm^®.

We have been in contact with IP patent attorneys to determine patentability of PermaDerm IP. We will proceed with patenting PermaDerm applications, manufacturing IP when funds become available.

Employees

As of September 30, ~~2021~~2022, we had 3 employees.

Subsidiaries

In September, 2013, Regenicin formed a wholly-owned subsidiary for the sole purpose of conducting research in the State of Georgia. This subsidiary has been inactive since its formation.

On August 31, 2022, we filed articles of continuance with the states of Nevada and Wyoming effectively moving our organizational jurisdiction from Nevada to Wyoming effective on that date.

Item 1A. Risk Factors.

A smaller reporting company is not required to provide the information required by this Item.

Table of Contents

Item 1B. Unresolved Staff Comments.

A smaller reporting company is not required to provide the information required by this Item.

Item 2. Properties

Our principal executive offices are located at 10 10 High Court, Little Falls, NJ 07424. Our headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by ~~Randall~~ Randall McCoy, our Chief Executive Officer. The office is attached to his residence but has its own entrances, ~~restroom~~rest room and kitchen facilities. No rent is charged.

We also maintain an office at 3 Arvida Drive, Pennington NJ 08534, which is an FDA registered, cGMP compliant FDA audited facility. This office is owned by Materials Testing Laboratory, and the principal is an officer of our company. No rent is charged.

Item 3. Legal Proceedings

On September 30, 2013, we filed a lawsuit against Lonza Walkersville and others in Fulton County Superior Court in the State of Georgia.

On November 7, 2014, we entered into an Asset Purchase Agreement (“the Agreement”) with Amarantus Bioscience Holdings, Inc., (“Amarantus”) and others in which we agreed to sell to Amarantus all of our rights and claims in our litigation currently pending in the “Lonza Litigation”. As part of the Agreement, we also granted to Amarantus an exclusive five (5) year right of first refusal to license any engineered skin we developed for the treatment of patients designated as severely burned. This option expired on November 7, 2019.

Other than as mentioned above, we have no threatened or pending litigation.

Item 4. Mine Safety Disclosures

N/A

Table of Contents

PART II

Market Information

Our common stock iswas previously quoted under the symbol “RGIN” on the OTCBB operated by the Financial Industry Regulatory Authority, Inc. (“FINRA”) and the OTCQB operated by OTC Markets Group, Inc. Few market makers continue to participate in the OTCBB system because of high fees charged by FINRA. ~~Consequently,~~and ~~market makers~~we ~~that~~are ~~once~~not quoted ~~our~~at ~~shares~~all onbecause ~~the~~of ~~OTCBB~~our ~~system~~failure ~~may~~in nothe ~~longer~~past befew ~~posting~~years ato ~~quotation~~provide ~~for~~audited ~~our~~financial ~~shares~~information. ~~As of the date of this report~~Consequently, ~~however,~~market ~~our~~makers ~~shares~~that ~~are~~once quoted byour ~~several~~shares ~~market makers~~ on the ~~OTCQB.~~OTCBB ~~The~~system ~~criteria~~no ~~for~~longer ~~listing~~are onposting ~~either~~any ~~the~~quotation ~~OTCBB~~and ortrades ~~OTCQB~~ are ~~similar and~~not ~~include~~generally ~~that~~available on wethis ~~remain~~or ~~current~~other inmarket ~~our SEC~~ reporting services.

Only a limited market exists for the purchase and sale of our securities. There is no assurance that a regular trading market will ever develop again, or if developed, that it will be sustained. Therefore, a shareholder may be unable to resell his securities in our company. Moreover, as a result of the limited trading and information on the pricing of our stock we are unable to provide a table showing a range of high and low bid quotations for our common stock during recent periods and we believe that any such information would be misleading because of the difficulty in determining these quotations.

The following table sets forth the range of high and low bid quotations for our common stock for each of the periods indicated as reported by the OTCQB. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

Fiscal Year Ending September 30, 2021
Quarter Ended		High $		Low $
	September 30, 2021		0.020		0.020
	June 30, 2021		0.029		0.029
	March 31, 2021		0.020		0.020
	December 31, 2020		0.016		0.014
Fiscal Year Ending September 30, 2020
Quarter Ended		High $		Low $
	September 30, 2020		0.012		0.012
	June 30, 2020		0.013		0.012
	March 31, 2020		0.019		0.017
	December 31, 2019		0.018		0.018

Penny Stock

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a market price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that: (a) contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; (b) contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation of such duties or other requirements of the securities laws; (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price; (d) contains a toll-free telephone number for inquiries on disciplinary actions; (e) defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and (f) contains such other information and is in such form, including language, type size and format, as the SEC shall require by rule or regulation.

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statement showing the market value of each penny stock held in the customer's account.

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement as to transactions involving penny stocks, and a signed and dated copy of a written suitability statement.

These disclosure requirements may have the ~~effect~~ effect of reducing the trading activity for our common stock. Therefore, stockholders may have additional difficulty selling our securities.

Table of Contents

Holders of Our Common Stock

As of December 31, ~~2021~~2022, we had 153,483,050 shares of our common stock issued and outstanding, held by 112 shareholders of record, with others holding shares in street name.

Dividends

There are no restrictions in our articles of incorporation or bylaws that prevent us from declaring dividends. The Nevada Revised Statutes, however, do prohibit us from declaring dividends where after giving effect to the distribution of the dividend:

1. we would not be able to pay our debts as they become due in the usual course of business, or;

2. our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the distribution.

We have not declared any dividends and we do not plan to declare any dividends in the foreseeable future.

Recent Sales of Unregistered Securities

For the fiscal years ended September 30, ~~2021~~ 2022 and September 30, ~~2020~~2021, we did not issue common stock.

Shares and Warrants to be issued:

No warrants were issued in ~~2020-~~fiscal years ended September 2021 or 2022.

Securities Authorized for Issuance under Equity Compensation Plans

The following table provides information about our compensation plans under which shares of common stock may be issued upon the exercise of options as of September 30, ~~2021~~2022.

Plan Category	Number of securities to be issued upon exercise of outstanding option, warrants and rights		Weighted-average exercise price of outstanding options, warrants and rights		Number of securities remaining available for future issuances under equity compensation plans
Equity compensation plans approved by security holders		0		0		0
Equity compensation plans not approved by security holders		11,771,344	$	0.02		0
Total		11,771,344	$	0.02		0

On December 15, 2010, the board of directors approved the Regenicin, Inc. 2010 Incentive Plan (the “Plan”). The Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, stock units, performance shares and performance units to our employees, officers, directors and consultants, including incentive stock options, non-qualified stock options, restricted stock, and other benefits. The Plan provides for the issuance of up to 3,542,688 shares of our common stock.

On January 6, 2011, we approved the issuance of 885,672 options to each of the four members of the board of directors at an exercise price is $0.62 per share. The options ~~vest~~vested over a three-year period and expire on December 22, 2015. On May 11, 2011, the terms of the options were amended to allow for immediate vesting. On December 10, 2013, we approved the amendment to those options to change the exercise price to $0.035 per share. On December 22, 2015 the Board extended the term of the options to December 31, ~~2019~~2021, and then extended the term of these options again with regard to its current active board members until December 31, 2023.

In addition, on January 15, 2015, the company entered into a stock option agreement with an officer of the company. The agreement grants the officer an option to purchase 10 million shares of common stock at $0.02 per share, and was to expire January 15, ~~2019~~2021. This option grant was extended by action of the Board of Directors until December 31, 2023.

Table of Contents

Warrants Issued and Outstanding

No warrants were outstanding at September 30, ~~2021~~2022.

Item 6. Selected Financial Data

A smaller reporting company is not required to provide the information required by this Item.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

See discussion in section marked: ‘Our Business Moving Forward In ~~2022~~2023’

Results of Operations for the ~~Years~~Fiscal Years Ended September 30, ~~2021~~2022 and ~~2020~~2021

We generated no revenues from September 6, 2007 (date of inception) to September 30, ~~2021~~2022. ~~We do not expect to generate revenues until we are able to obtain FDA approval of cell therapy and biotechnology products and thereafter successfully market and sell those products.~~

We incurred operating expenses of $~~842~~601,~~364~~179 for the year ended September 30, ~~2021~~2022, compared with operating expenses of $ ~~663~~635,~~749~~864 for the year ended September 30, ~~2020~~2021. Our operating expenses ~~increased~~decreased in ~~2021~~2022 from ~~2020~~2021, and are compared as follows:

Operating Expenses	September 30, ~~2021~~2022		September 30, ~~2020~~2021
General and Administrative	$	~~842~~635,~~364~~864	$	663,749
Stock Based Compensation	$	38,083	$	34,738

We incurred net other expense of $3438,~~738~~083 for the year ended September 30, ~~2021~~2022, as compared to net other expense of $4834,~~775~~738 for the year ended September 30, ~~2020~~ 2021. Our other income and expenses for ~~2021~~2022 consisted of interest expenses of $3436,~~713~~258 and a loss on other than temporary decline in the fair value of Amarantus stock of $ 25 1,825. Our other income and expenses for ~~2020~~2021 consisted of ~~only~~ interest expenses of $4734,~~050~~713 and a loss on other than temporary decline in the fair value of Amarantus stock of $~~1,725~~25.

We had a net loss of $~~877~~639,~~102~~262 for the year ended September 30, ~~2021~~2022, as compared with a loss of $~~559~~670,~~591~~602 for the prior year. The ~~increase~~decrease in loss was due to the reversal of accounts payable in the year ended September 30, ~~2020~~2022 of $~~152~~31,~~933~~340, which ~~increased~~decreased the loss.

Our net loss attributable to common stockholders ~~for~~ for the year ended September 30, ~~2021~~2022 was $~~947~~692,~~507~~216 compared to a net loss of $~~630~~741,~~583~~007 for the year ended September 30, ~~2020~~2021. The ~~increase~~ decrease in loss ~~of $316,924~~ was ~~primarily~~ due to ~~an increase in general and administrative expense of $178,615, a decrease in interest expense of $14,037 due to an interest catch up in 2020, a $587 decrease in preferred stock dividend and~~ the reversal of accounts payable ~~of $152,933~~ in the year ended September 30, ~~2020~~2022 of $48,791.

Table of Contents

Liquidity and Capital Resources

As of September 30, ~~2021~~2022, we had cash of $114,~~859~~568 and investments of $2925,~~750,~~ for total current assets of $415,~~609~~493. Our total current liabilities as of September 30, 2021 were $5,~~034~~612,~~987~~633. We ~~had~~ had a working capital deficit of $5,~~168~~597,~~987~~140 as of September 30, ~~2021~~2022.

Operating activities used a net $2427,~~107~~291 in cash for the year ended September 30, ~~2021~~2022. Financing activities provided $2440,~~600~~000 for the year ended September 30, ~~2021~~2022 and consisted entirely of proceeds from loans from officers.

We have issued various promissory notes over the course of the last several fiscal years in order to continue funding our operations. The terms of these promissory notes are ~~detailed~~ detailed in Note GF to the financial statements accompanying this Annual Report. While this financing has been helpful in the short term to meet our financial obligations, we ~~will~~have ~~need~~been ~~additional~~seeking other types of financing to fund our operations, ~~continue with the FDA approval process, and implement our business plan~~ over the ~~long term. We will thus once again be seeking additional financing during the fiscal year end September 30,~~coming ~~2022~~year.

Going Concern

Our financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred cumulative losses to date, expect to incur further losses in the development of our business, and have been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

Accordingly, this is the policy we believe is the most critical to aid in fully understanding and evaluating our financial condition and results of operations.

1. Income Taxes - The Company accounts for income taxes in accordance with accounting guidance FASB ASC 740, " Income Taxes ," which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized. The Company has adopted the provisions of FASB ASC 740-10-05 " Accounting for Uncertainty in Income Taxes ." The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

Development Stage Activities and Operations

The Company is in the development stage and has had no revenues ~~other~~for ~~than~~ the ~~sale~~current ofreported ~~its assets to Amarantus~~year. A development stage company is defined as one in which all efforts are devoted substantially to establishing a new business and even if planned principal operations have commenced, revenues are insignificant.

Table of Contents

Recently Issued Accounting Pronouncements

Any recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the condensed financial statements of the Company.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 8. Financial Statements and Supplementary Data

Index to Financial Statements Required by Article 8 of Regulation S-X:

The consolidated financial statements as of and for the years ended September 30, 2021 and 2020 have not been audited by our independent registered public accounting firm. See Item 14 for more additional information.

UNAUDITED Financial Statements:
F-1	Consolidated Balance Sheets as of September 30, 2022 and 2021
F-2	Consolidated Statements of Operations for the years ended September 30, 2022 and September 30, 2021
F-3	Consolidated Statement of Stockholders’ Deficiency for the years ended September 30, 2022 and September 30, 2021
F-4	Consolidated Statements of Cash Flows for the years ended September 30, 2022 and September 30, 2021
F-5	Notes to Consolidated Financial Statements

UNAUDITED Financial Statements:
F-1	Consolidated Balance Sheets as of September 30, 2021 and 2020
F-2	Consolidated Statements of Operations for the years ended September 30, 2021 and September 30, 2020
F-3	Consolidated Statement of Stockholders’ Deficiency for the years ended September 30, 2021 and September 30, 2020
F-4	Consolidated Statements of Cash Flows for the years ended September 30, 2021 and September 30, 2020
F-5	Notes to Consolidated Financial Statements

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	September 30, 2021			September 30, 2020
	September 30, 2022			September 30, 2021
ASSETS
CURRENT ASSETS
Cash	$	114,~~859~~569		$	1,~~366~~859
Common stock of Amarantus		~~2,750~~925			2,~~775~~750
Total current and total assets	$	415,~~609~~493		$	4,~~141~~609
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
CURRENT LIABILITIES
Accounts payable	$	93103,~~674~~119		$	8893,~~659~~674
Accrued expenses - other (related party of $41,925 and $29,552)		441,394			174,438
Accrued expenses - other (related party of $65,471 and $46,713)		254,595			234,894
Accrued salaries - officers		4,~~031~~612,001			34,~~450~~031,~~002~~001
Promissory note payable		175,000			175,000
Convertible promissory note - officer		335,683			335,683
Loan payable		10,000			10,000
Loans payable - officer		82122,235			5782,~~635~~235
Total current and total liabilities		5,~~168~~612,~~987~~633			4,~~291~~962,~~417~~487
STOCKHOLDERS' DEFICIENCY
Series A 8% Convertible Preferred stock, $0.001 par value, 5,500,000 shares authorized; 885,000 issued and outstanding		885			885
Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding		157,914			157,914
Additional paid-in capital		10,208,339			10,208,339
Accumulated deficit		(15,~~527~~959,~~088~~850	)		(1415,~~649~~320,~~986~~588	)
Less: treasury stock; 4,428,360 shares at par		(4,428	)		(4,428	)
Total stockholders' deficiency		(5,~~164~~597,~~378~~140	)		(4,~~287~~957,~~276~~878	)
Total liabilities and stockholders' deficiency	$	415,~~609~~493		$	4,~~141~~609

See Notes to Consolidated Financial Statements.

F-1

Table of Contents

REGENICIN, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Year Ended September 30, 2021			Year Ended September 30, 2020
	Year Ended September 30, 2022			Year Ended September 30, 2021
Revenues	$	—		$	—
Operating expenses
General and administrative		~~842~~601,~~364~~179			~~663~~635,~~749~~864
Total operating expenses		~~842~~601,~~364~~179			~~663~~635,~~749~~864
Operating loss before other operating income		(842,364	)		(663,749	)
Operating loss before other expenses		(601,179	)		(635,864	)
Other operating income - reversal of accounts payable		—			152,933
Loss from operations		(842,364	)		(510,816	)
Other expenses
Interest expense related party of $(17,213), $(25,271)		(34,713	)		(47,050	)
Interest expense related party of $(18,758), $(17,213)		(36,258	)		(34,713	)
Change in unrealized loss on securities		(251,825	)		(~~1,725~~25	)
Total other expenses		(3438,~~738~~083	)		(4834,~~775~~738	)
Net loss		(~~877~~639,~~102~~262	)		(~~559~~670,~~591~~602	)
Preferred stock dividends		(7052,~~405~~954	)		(70,~~992~~405	)
Net loss attributable to common stockholders	$	(~~947~~692,~~507~~216	)	$	(~~630~~741,~~583~~007	)
Loss per share basic	$	(0.0100	)	$	(0.00	)
Loss per share diluted	$	(0.0100	)	$	(0.00	)
Weighted average number of shares outstanding basic		153,483,050			153,483,050
Weighted average number of shares outstanding diluted		153,483,050			153,483,050

See Notes to Consolidated Financial Statements.

F-2

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIENCY

(UNAUDITED)

							Accumulated
					Additional
					Additional		Other
	Convertible Preferred Stock		Common Stock		Paid-in	Accumulated	Treasury
	Convertible Preferred Stock		Common Stock		Paid-in	Accumulated	Comprehensive	Treasury
	Shares	Amount	Shares	Amount	Capital	Deficit	Stock (1)	Total
	Shares	Amount	Shares	Amount	Capital	Deficit	Income	Stock (1)	Total
Balances at October 1, 2021	885,000	$ 885	157,911,410	$ 157,914	$ 10,208,339	$ (15,320,588)	$ (4,428)	(4,957,878)
Balances at October 1, 2020	885,000	$ 885	157,911,410	$ 157,914	$ 10,208,339	$ (14,649,986)	—	$ (4,428)	(4,287,276)
Net loss	—	—	—	—	—	(639,262)	—	(639,262)
Net loss	—	—	—	—	—	(877,102)	—	—	(877,102)
Balances at September 30, 2022	885,000	$ 885	157,911,410	$ 157,914	$ 10,208,339	$ (15,959,850)	$ (4,428)	$ (5,597,140)
Balances at September 30, 2021	885,000	$ 885	157,911,410	$ 157,914	$ 10,208,339	$ (15,527,088)	—	$ (4,428)	$ (5,164,378)
Balances at October 1, 2020	885,000	$ 885	157,911,410	$ 157,914	$ 10,208,339	$ (14,649,986)	$ (4,428)	(4,287,276)
Balances at October 1, 2019	885,000	$ 885	157,911,410	$ 157,914	$ 10,208,339	$ (14,090,395)	—	$ (4,428)	(3,727,685)
Net loss	—	—	—	—	—	(670,602)	—	(670,602)
Net loss	—	—	—	—	—	(559,591)	—	—	(559,591)
Balances at September 30, 2021	885,000	$ 885	157,911,410	$ 157,914	$ 10,208,339	$ (15,320,588)	$ (4,428)	$ (4,957,878)
Balances at September 30, 2020	885,000	$ 885	157,911,410	$ 157,914	$ 10,208,339	$ (14,649,986)	—	$ (4,428)	$ (4,287,276)

(1) The number of shares in treasury stock for all periods presented was 4,428,360.

See Notes to Consolidated Financial Statements.

F-3

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

		Year Ended September 30, 2021			Year Ended September 30, 2020
		Year Ended September 30, 2022			Year Ended September 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(~~877~~639,~~102~~262	)	$	(~~559~~670,~~591~~602	)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized loss on investment		251,825			~~1,725~~25
Accrued interest on loans and notes payable		3436,~~713~~258			4734,~~050~~713
Stock based compensation - general and administrative		—			—
Reversal of accounts payable		—			(152,933	)
Changes in operating assets and liabilities
Accounts payable		59,~~015~~443			~~103~~5,~~294~~015
Accrued expenses - other		~~232~~(16,~~243~~555	)		~~(143~~25,~~745~~743	)
Accrued salaries - officers		~~580~~581,~~999~~000			~~581~~580,~~001~~999
Net cash used in operating activities		(2427,~~107~~291	)		(~~123~~24,~~199~~107	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds of loans from officers		2440,~~600~~000			~~123~~24,~~750~~600
Net cash provided by financing activities		2440,~~600~~000			~~123~~24,~~750~~600
NET DECREASE IN CASH		493			551
NET INCREASE IN CASH		12,709			493
CASH - BEGINNING OF PERIOD		1,~~366~~859			~~815~~1,366
CASH - END OF PERIOD	$	114,~~859~~568		$	1,~~366~~859
Supplemental disclosures of cash flow information:
Cash paid for interest	$	—		$	—
Cash paid for taxes	$	—		$	—
Non-cash activities:
Issuance of convertible promissory note in exchange for loan payable - officer	$	—		$	335,683

See Notes to Consolidated Financial Statements.

F-4

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE A - THE COMPANY

Regenicin, Inc. ("Regenicin"), formerly known as Windstar, Inc., was incorporated in the state of Nevada on September 6, 2007. On July 19, 2010, the Company amended its Articles of Incorporation to change the name of the Company to Regenicin, Inc. InOn ~~September~~August ~~2013~~31, ~~Regenicin formed~~2022, awe ~~new~~filed ~~wholly-owned~~articles ~~subsidiary for the sole purpose~~ of ~~conducting~~continuance ~~research~~with in the ~~State~~states of ~~Georgia~~Nevada ~~(together, the "Company").~~and ~~The~~Wyoming ~~subsidiary~~effectively ~~has~~moving noour ~~activity~~organizational ~~since~~jurisdiction ~~its~~from ~~formation~~Nevada ~~due~~ to ~~the~~Wyoming ~~lack~~effective ofon ~~funding~~that date. The Company's business plan is to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation:

The accompanying consolidated financial statements include the accounts of Regenicin and its wholly owned subsidiary. All significant inter-company balances and transactions have been eliminated.

Going Concern:

The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and as of September 30, ~~2021~~2022, has an accumulated deficit of approximately $15.5395 million from inception, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Currently management plans to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Income (loss) per share:

Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period; only in periods in which such effect is dilutive.

The following securities have been excluded from the calculation as the exercise price was greater than the average market price of the common shares:

	2021		2020
	2022		2021
Options		—		—

The following weighted average securities have been excluded from the calculation even though the exercise price was less than the average market price of the common shares because the effect of including these potential shares was anti-dilutive due to the net losses incurred during ~~2021~~2022 and ~~2020~~2021:

	2021		2020
	2022		2021
Options		11,771,344		11,771,344
Convertible Preferred Stock		8,850,000		8,850,000
Convertible Promissory Note		1635,~~784~~712,~~150~~910		3016,~~079~~784,~~500~~150
Shares excluded from the calculation of diluted loss per share		3756,~~405~~334,~~494~~254		5037,~~700~~405,~~844~~494

F-5

Table of Contents

Financial Instruments and Fair Value Measurement:

As of October 1, 2018, the Company adopted ASU No. 2016-01, "Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities." The new standard principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There no longer is an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. As a result of the adoption, the Company recorded a cumulative effect adjustment of a $950 decrease to accumulated other comprehensive income, and a corresponding decrease to accumulated deficit, as of October 1, 2018.

Common stock of Amarantus BioScience Holdings, Inc. ("Amarantus") is carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, and unrealized gains and losses are included in other income (expense) on the statement of operations.

The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at September 30, ~~2021~~2022 is $~~2,750~~925. The change in unrealized loss for the year ended September 30, ~~2021~~2022 and ~~2020~~2021 was $~~(25)~~1,825 and $~~(1,725)~~25 net of income taxes, respectively, and was reported as other expense.

The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company’s consolidated balance sheets approximated their values as of and September 30, ~~2021~~2022 and ~~2020~~2021 due to their short-term nature.

Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimation includes the selection of assumptions underlying the calculation of the fair value of options. Actual results could differ from those estimates.

Stock-Based Compensation:

The Company accounts for stock-based compensation in accordance with FASB ASC 718, “Compensation - Stock Compensation.” Under the fair value recognition provision of the ASC, stock-based compensation cost is estimated at the grant date based on the fair value of the award. The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option pricing model.

The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505, “Equity.” Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC 505.

F-6

Table of Contents

Income Taxes:

The Company accounts for income taxes in accordance with accounting guidance FASB ASC 740, "Income Taxes," which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.

The Company has adopted the provisions of FASB ASC 740-10-05 "Accounting for Uncertainty in Income Taxes." The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements. The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

Recently Issued Accounting Pronouncements:

NOTE C – LICENSE OF RIGHTS

On November 7, 2014, the Company entered into a Sale Agreement, as amended on January 30, 2015, with Amarantus BioScience Holdings, Inc. (“Amarantus”). Under the Sale Agreement, the Company granted to Amarantus an exclusive five (5) year option to license any engineered skin designed for the treatment of patients designated as severely burned by the FDA developed by the Company. Amarantus could exercise this option at a cost of $10,000,000 plus a royalty of 5% on gross revenues in excess of $150 million. The option had not been exercised and had since expired.

NOTE D – ~~ACCOUNTS~~ACCRUED ~~PAYABLE~~EXPENSES

In Fiscal 2020, management determined that certain accounts payables on the balance sheet for over six years totaling $152,933 were no longer due and payable. These amounts have been reversed and are included as a separate component of loss from operations.

NOTE E - ACCRUED EXPENSES

Accrued expenses consisted of the following:

	2021		2020
	2022		2021
Professional fees	$	~~232~~9,~~243~~186	$	—25,743
Interest		~~209~~245,~~151~~409		~~174~~209,~~438~~151
Accrued expenses	$	~~441~~254,~~394~~595	$	~~174~~234,~~438~~894

F-7

Table of Contents

NOTE E F - LOANS PAYABLE

Convertible Promissory Note - Officer:

Through March 31, 2020, John Weber, the Company's Chief Financial Officer, advanced the Company a total of $335,683. On March 31, 2020, these advances were converted into a convertible promissory note. Interest on the note is computed at 5% per annum and accrues from the time of the advances until the maturity date. The original maturity date was September 30, 2020, at which time all the accrued interest and principal became due. The note has been extended several times and most recently to September 30, ~~2023~~2022. For the years ended September 30, ~~2021~~2022 and ~~2020~~2021 ~~related party~~ interest totaling $1718,~~213~~758 and $2517,~~271~~213 respectively was incurred and accrued. ~~Accrued~~Lifetime accrued interest on the note was $4165,~~925~~471 and $2946,~~552~~713 at September 30, ~~2021~~2022 and ~~2020~~2021, respectively, which is included in accrued expenses on the accompanying consolidated balance sheets The note is convertible at the option of Mr. Weber into shares of the Company's common stock at the prevailing market rate on the date of conversion.

Loan Payable:

In February 2011, an investor advanced $10,000. The loan does not bear interest and is due on demand. At both September 30, ~~2021~~2022 and ~~2020~~2021, the loan payable totaled $10,000.

Loans Payable - Officer:

Through September 30, 2019, J. Roy Nelson, the Company's Chief Science Officer, made net advances to the Company totaling $26,935. The loans do not bear interest and are due on demand.

In September 2018, Randall McCoy, the Company's Chief Executive Officer, advanced to the Company $4,500. The loan does not bear interest and is due on demand.

From July 2020 to September ~~2021~~2022, John Weber, the Company’s Chief Financial Officer, advanced to the Company a total of $5090,800. The ~~loan~~bears ~~does~~interest ~~not~~at ~~bear~~5% ~~interest~~per annum and is due on demand.

NOTE GF – PROMISSORY NOTES PAYABLE

Bridge Financing:

On December 21, 2011, the Company issued a $150,000 promissory note to an individual. The note bore interest so that the Company would repay $175,000 on the maturity date of June 21, 2012. Additional interest of 10% was charged on any late payments. The note was not paid at the maturity date and the Company is incurring additional interest as described above. At both September 30, ~~2021~~2022 and ~~2020~~2021, the note balance was $175,000. Interest expense was $17,500 for each of the years ended September 30, ~~2021~~2022, and ~~2020~~2021, respectively. Accrued interest on the note was $~~162~~179,~~438~~ 938 and $~~144~~162,~~938~~ 438 at September 30, ~~2021~~2022 and ~~2020~~ 2021, respectively, which is included in accrued expenses on the accompanying consolidated balance sheets.

NOTE HG - RELATED PARTY TRANSACTIONS

The Company’s principal executive offices are located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Mr. McCoy. The office is attached to his residence but has its own entrances, restroom and kitchen facilities.

The Company also maintains an office at Carbon & Polymer Research Inc. ("CPR") in Pennington, New Jersey, which is the Company's materials and testing laboratory. An officer of the Company is an owner of CPR. No rent is charged for either premise.

On May 16, 2016, the Company entered into an agreement with CPR in which CPR will supply the collagen scaffolds used in the Company's production of the skin tissue. The contract contains a most favored customer clause guaranteeing the Company prices equal or lower than those charged to other customers. The Company has not yet made purchases from CPR.

See ~~Note F~~ NoteE for loans payable to related parties.

F-8

Table of Contents

NOTE I H - INCOME TAXES

The Company did not incur current income tax expense for either of the years ended September 30, ~~2021~~2022 or ~~2020~~2021.

At September 30, ~~2021~~2022, the Company had available approximately $4.76 million of net operating loss (“NOL”) carry forwards which expire in the years 2029 through 2037. However, the use of the net operating loss carryforwards ~~generated~~may ~~prior~~be ~~to September 30, 2011 totaling $0.7 million is~~ limited under Section 382 of the Internal Revenue Code. Section 382 of the Internal Revenue Code of 1986, as amended (the Code), imposes an annual limitation on the amount of taxable income that may be offset by a corporation’s NOLs if the corporation experiences an “ownership change” as defined in Section 382 of the Code. The Company has not yet undertaken the process to calculate these changes.

Significant components of the Company’s deferred tax assets at September 30, ~~2021~~2022 and ~~2020~~2021 are as follows:

	2021			2020
	2022			2021
Net operating loss carry forwards	$	1,~~285~~235,~~325~~018		$	1,~~224~~229,~~993~~570
Unrealized loss		~~807~~808,~~975~~940			807,975
Stock based compensation		17,061			817,~~322~~061
Accrued expenses		1,~~091~~247,~~070~~940			~~777~~1,~~330~~091,070
Total deferred tax assets		3,~~201~~308,~~431~~959			23,~~818~~145,~~620~~676
Valuation allowance		(3,~~201~~308,~~431~~959	)		(23,~~818~~145,~~620~~676	)
Net deferred tax assets	$	—		$	—

Due to the uncertainty of their realization, a valuation allowance has been established for all of the income tax benefit for these deferred tax assets.

The following is a reconciliation of the Company’s income tax rate using the federal statutory rate to the actual income tax rate as of September 30, ~~2021~~2022 and ~~2020~~2021:

	2021			2020
	2022			2021
Federal tax rate		(21	)%		(21	)%
Effect of state taxes		(6	)%		(6	)%
Effect of NOL		(2	)%		(2	)%
Change in valuation allowance		25	%		25	%
Total		0	%		0	%

At September 30, ~~2021~~2022 and ~~2020~~2021, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. As of September 30, ~~2021~~2022, and ~~2020~~2021 the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.

The Company files its federal and state income tax returns under a statute of limitations. The tax years ended September 30, ~~2018~~2020 through September 30, ~~2021~~2022 generally remain subject to examination by federal tax authorities.

F-9

Table of Contents

NOTE I J - STOCKHOLDERS’ DEFICIENCY

Preferred Stock:

Series A

Series A Preferred earns a dividend of 8% per annum on the stated value and has a liquidation preference equal to the stated value of the shares ($885,000 liquidation preference as of September 30, ~~2021~~2022 and ~~2020~~2021 plus dividends in arrears as per below). Each share of Preferred Stock has an initial stated value of $1 and is convertible into shares of the Company’s common stock at the rate of 10 for 1.

The Series A Preferred Stock was marketed through a private placement memorandum that included a reference to a ratchet provision which would have allowed the holders of the stock to claim a better conversion rate based on other stock transactions conducted by the Company during the three-year period following the original issuance of the shares. The Certificate of Designation does not contain a ratchet provision. Certain of the stock related transactions consummated by the Company during this time period may have triggered this ratchet provision, and thus created a claim by holders of the Series A Preferred Stock who purchased based on this representation for a greater conversion rate than initially provided. There have been no new developments related to the remaining Series A holders regarding this claim and the conversion rate of their Series A Preferred Stock. Changes to the preferred stock conversion ratio may result in modification or extinguishment accounting. That may result in a deemed preferred stock dividend which would reduce net income available to common stockholders in the calculation of earnings per share. Certain of the smaller Series A holders have already converted or provided notice of conversion of their shares. In respect of this claim, the Company and its outside counsel determined that it is not possible to offer an opinion regarding the outcome. An adverse outcome could materially increase the accumulated deficit.

The dividends are cumulative commencing on the issue date when and if declared by the Board of Directors. As of September 30, ~~2021~~2022, and ~~2020~~2021, dividends in arrears were $~~747~~818,~~230~~030 ($.8492 per share) and $~~676~~747,~~430~~232 ($.7684 per share), respectively.

At both September 30, ~~2021~~2022 and ~~2020~~2021, 885,000 shares of Series A Preferred were outstanding.

Series B

On January 23, 2012, the Company designated a new class of preferred stock called Series B Convertible Preferred Stock (“Series B Preferred”). 4,000,000 shares have been authorized with a liquidation preference of $2.00 per share. Each share of Series B Preferred is convertible into ten shares of common stock. Holders of Series B Preferred have a right to a dividend (pro-rata to each holder) based on a percentage of the gross revenue earned by the Company in the United States, if any, and the number of outstanding shares of Series B Convertible Preferred Stock, as follows: Year 1 - Total Dividend to all Series B holders = .03 x Gross Revenue in the U.S. Year 2 - Total Dividend to all Series B holders = .02 x Gross Revenue in the U.S. Year 3 - Total Dividend to all Series B holders = .01 x Gross Revenue in the U.S. At September 30, 2021, and 2020 no shares of Series B Preferred are outstanding.

2010 Incentive Plan:

On December 15, 2010, the board of directors approved the Regenicin, Inc. 2010 Incentive Plan (the “Plan”). The Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, stock units, performance shares and performance units to the Company’s employees, officers, directors and consultants. The Plan provides for the issuance of up to 4,428,360 shares of the Company’s common stock.

Effective October 1, 2019, the Company adopted ASU No. 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU 2018-07 expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The adoption of ASU 2018-07 did not have a significant impact on the Company’s consolidated financial statements.

On January 6, 2011, the Company approved the issuance of 885,672 options to each of the four members of the board of directors at an exercise price of $0.035, as amended, per share that were to expire, as extended, on December 31, 2018. Effective as of the expiration date, the Company extended the term of those options for two of the directors to December 31, 2023. All other contractual terms of the options remained the same. The option exercise price was compared to the fair market value of the Company's shares on the date when the extension was authorized by the Company, resulting in the immediate recognition of $1,316 in compensation expense. There is no deferred compensation expense associated with this transaction, since all extended options had previously been fully vested. The extended options were valued utilizing the Black-Scholes option pricing ~~model~~ model with the following assumptions: Exercise price of $0.035, expected volatility of 25.54%, risk free rate of 2.51% and expected term of 5 years.

On January 15, 2015, the Company approved the issuance of 10,000,000 options to one of its Officers at an exercise price of $0.02, per share that were set to expire on January 15, 2019. Effective December 31, 2019, the Company extended the term of those options to December 31, 2023. All other contractual terms of the options remained the same. The option exercise price was compared to the fair market value of the Company’s shares on the date when the extension was authorized by the Company, resulting in the immediate recognition of $29,508 in compensation expense, which is included in the results of operations for the year ended September 30, 2021. There is no deferred compensation expense associated with this transaction, since all extended options had previously been fully vested. The extended options were valued utilizing the Black-Scholes option pricing model with the following assumptions: Exercise price of $0.02, expected volatility of 25.54%, risk free rate of 2.51% and expected term of 5 years

Expected life is determined using the “simplified method” permitted by Staff Accounting Bulletin No. 107. The stock volatility factor is based on the Nasdaq Biotechnology Index. The Company did not use the volatility rate for Company’s common stock as the Company’s common stock had not been trading for the sufficient length of time to accurately compute its volatility when these options were issued.

No stock based compensation was recorded the years ended September 30, ~~2021~~2022 and ~~2020~~2021.

F-10

Table of Contents

Option activity for ~~2021~~2022 and 2020 is summarized as follows:

	Options		Weighted Average Exercise Price
Options outstanding, October 1, 2020		1311,~~542~~771,~~688~~334	$	0.02019
Granted		—		—
Forfeited		~~1,771,344~~—		~~.035~~—
Options outstanding, September 30, 2020		11,771,344	$	0.019
Options outstanding, September 30, 2021		11,771,334	$	0.019
Granted		—		—
Forfeited		—		—
Options outstanding, September 30, 2021		11,771,344	$	0.019
Options outstanding, September 30, 2022		11,771,334	$	0.019
Aggregate intrinsic value	$	0

The aggregate intrinsic value was calculated based on the positive difference between the closing market price of the Company’s Common Stock and the exercise price of the underlying options.

The following table summarizes information regarding stock options outstanding at September 30, ~~2021~~2022:

				Weighted Average Remaining				Options Exercisable Weighted Average
Ranges of prices		Number Outstanding		Contractual Life		Exercise Price		Number Exercisable		Exercise Price
$	0.020		10,000,000		21.25	$	0.020		10,000,000	$	0.020
$	0.035		1,771,344		21.25	$	0.035		1,771,344	$	0.035
	$0.020-$0.035		11,771,~~344~~334		21.25	$	0.019		11,771,344	$	0.022

As of September 30, ~~2021~~2022, there was no unrecognized compensation cost related to non-vested options granted.

NOTE J K - SUBSEQUENT EVENTS

~~Management~~Subsequent ~~has~~to ~~evaluated~~the ~~subsequent~~end ~~events~~of ~~through~~this fiscal year, in October ~~the~~2022, ~~date~~we ofset up a new Nevada Series LLC called NovaDerm Product Package, LLC (“NPP LLC”). During November and December 2022, consistent with Nevada law governing this ~~filing~~Master Series LLC, we then establish twenty-five (25) individual series LLCs, identifying each with a series letter of A through T or AA through EE. Thus, each of these sub-entities were named NovaDerm Product Package Series A, LLC through Series T, LLC, and then Series AA to Series EE, LLC (or NPP-A through NPP-T and NPP-AA through NPP-EE for short).

Into each of these twenty-five individual Series LLCs, we contributed the right and exclusive ownership to a certain amount of the bovine hides and corium we currently own and use as key materials in the preparation of our NovaDerm® product, as well as the right to designate: (a) the specific patient cultured skin to be prepared from these materials; (b) the amount of this cultured skin to be prepared up to a designated amount and (c) the medical facility to receive the fully prepared and processed NovaDerm® cultured skin from these materials (these materials and combined designation rights are collectively referred to herein as the “NovaDerm® Product Rights”). For NPP-A through NPP-T and NPP-AA through NPP-CC we designated 33,333 cm² of these NovaDerm® Product Rights. For NPP-DD we designated 30,625 cm² of NovaDerm® Product Rights and for NPP-EE we designated 28,783 cm² of NovaDerm® Product Rights. Each contribution of each of the NovaDerm® Product Rights was provided in exchange for 100 membership interests in the Series LLC which represented 100% of all membership interests issued.

We subsequently transferred 99% of our membership interests (or 99 membership interests) in each of these Series LLC to various Limited Liability Companies, held by individuals unknown to us, in exchange for a pre-agreed payment. Prior to year-end, the members of these LLCs voted to donate 100% of the membership interests to charity.

F-11

Table of Contents

Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

No events occurred requiring disclosure under Item 304 of Regulation S-K during the fiscal year ending September 30, ~~2019~~2022.

Item 9A. Controls and Procedures

Disclosure Controls and Procedures

As required by Rule 13a-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this annual report, being September 30, ~~2019~~2022. This evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Based upon that evaluation, including our Chief Executive Officer and Chief Financial Officer, we have concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this annual report.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing ~~and~~ and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of September 30, ~~2019~~2022 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of September 30, ~~2019~~2022, our internal control over financial reporting was not effective. Our management identified the following material weaknesses in our internal control over financial reporting, which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

We plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this annual report on Form 10-K, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement the following changes during our fiscal year ending September 30, ~~2021~~2022, depending on available funds: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out in (i) and (ii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to an exemption for non-accelerated filers set forth in Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Table of Contents

Remediation of Material Weakness

We are unable to remedy our controls related to the inadequate segregation of duties and ineffective risk management until we receive financing to hire additional employees.

Limitations on the Effectiveness of Internal Controls

Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting are or will be capable of preventing or detecting all errors or all fraud. Any control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements, due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns may occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risk.

Item 9B. Other Information

None

Table of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The following table contains information with respect to our current executive officers and directors:

Name	Age		Principal Positions With Us
Randall McCoy		72	Chief Executive Officer and Director
John J. Weber		72	Chief Financial Officer and Director
Dr. J. Roy Nelson		73	Chief Science Officer

Randall McCoy has served as our Chief Executive Officer and director since July 2010. Prior to joining the Company, Mr. McCoy served as President of McCoy Enterprises LLC since its founding in May 2002. Mr. McCoy has more than 43 years of experience in the healthcare industry and has assisted both small and major pharmaceutical/device companies address FDA issues. He served as Laboratory Manager and Instructor at both George Washington University and Temple Medical School, and served as Program Manager at the Stanford Research Institute, Healthcare Division, of the David Sarnoff Research Center. Mr. McCoy has also helped over 225 foreign and domestic companies introduce their FDA regulated drug and medical device products into the US and world market. He currently holds over 30 US and international patents.

John J. Weber has served as our Chief Financial Officer and Director since September 13, 2010. Mr. Weber served as the Executive Vice President of Fujifilm Medical Systems, USA from 2006 until 2009. While at Fujifilm he was responsible for overseeing all corporate activity with the exception of R&D. In previous positions at Fujifilm he served as Senior Vice President of Operations as well as Chief Financial Officer.

Mr. Weber brings over 20 years of medical-related corporate, operational and financial management experience to the Company.

Dr. J. Roy Nelson Chief Science Officer owns and operates a FDA registered cGMP audited laboratory. The Material Testing Laboratory holds a Schedule I-V DEA drug license and with an electronic FDA submission portal. His laboratory provides material science supports for new medical devices and drug support for major pharmaceutical as well as smaller companies. In addition to numerous medical device and drug developmental projects, he has been on two FDA consent decree remediations writing SOPs and other FDA compliance documents. He has eight years experience working with various collagen products, such as sponges. Prior to 1988 Dr. Nelson was a senior material scientist at RCA/SRI in Princeton, NJ. He has more than twenty US patents. Dr. Nelson and Mr. McCoy have worked on numerous projects together since 1979 and share co-inventor positions on various patents.

Term of Office

Our directors are appointed for a one-year term to hold office until the next annual general meeting of our shareholders or until removed from office in accordance with our bylaws. Our officers are appointed by our board of directors and hold office until removed by the board.

Family Relationships

There are no family relationships between or among the directors, executive officers or persons nominated or chosen by us to become directors or executive officers.

Table of Contents

Involvement in Certain Legal Proceedings

To the best of our knowledge, during the past ten years, none of the following occurred with respect to a present or former director, executive officer, or employee: (1) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (2) any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) being subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his or her involvement in any type of business, securities or banking activities; and (4) being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

Committees of the Board

Our company currently does not have nominating, compensation or audit committees or committees performing similar functions nor does our company have a written nominating, compensation or audit committee charter. Our directors believe that it is not necessary to have such committees, at this time, because the functions of such committees can be adequately performed by the board of directors.

Our company does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for directors. The board of directors believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. Our company does not currently have any specific or minimum criteria for the election of nominees to the board of directors and we do not have any specific process or procedure for evaluating such nominees. The board of directors will assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.

A shareholder who wishes to communicate with our board of directors may do so by directing a written request addressed to our CEO and director, Randall McCoy, at the address appearing on the first page of this annual report.

Code of Ethics

We have adopted a Code of Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the Code of Ethics is attached to our Annual Report on Form 10-K for the year ended September 30, 2011 as Exhibit 14.1.

Table of Contents

Item 11. Executive Compensation

Compensation Discussion and Analysis

Employment Agreement with Randall McCoy

On July 16, 2010, we entered into an employment agreement with Mr. Randall McCoy. The employment agreement has a three-year term that automatically extends in three-year increments unless notice of non-renewal is given by either party at least ninety (90) days prior to the expiration of the then current term.

The July 16, 2010, employment agreement provided for an initial annual base salary of $250,000. Under an addendum to the employment agreement, however, dated August 2, 2010, Mr. McCoy will earn an annual base salary of $125,000 until such time as we achieve a positive net income for the preceding calendar quarter as determined in accordance with GAAP and reported in our financial statements filed with the Securities and Exchange Commission under the Securities and Exchange Act of 1934, as amended. Immediately upon our attaining such positive net income, Mr. McCoy’s annual base salary will be increased to $250,000 as stated in the July 16, 2010 employment agreement.

The annual base salary will be reviewed each year by our board of directors (or compensation committee, if we then have one), but cannot be decreased from the amount in effect in the previous year. Pursuant to the employment agreement, Mr. McCoy is eligible for an annual bonus determined by our board of directors (or compensation committee, if any). The employment agreement also provides that Mr. McCoy is eligible to participate in our equity incentive plans and other employee benefit programs.

Mr. McCoy’s employment agreement imposes on him post-termination non-competition, non-solicitation and confidentiality obligations. Under the agreement, he agrees not to compete with our business in the United States, subject to certain limited exceptions, for a period of one year after termination of his employment. Mr. McCoy further agrees, for a period of one year after termination of his employment, to refrain from (i) soliciting, inducing, encouraging or attempting to induce or encourage any employee, contractor or consultant of the Company to terminate his or her employment or relationship with Company, or to breach any other obligation to Company; and (ii) soliciting, interfering with, disrupting, altering or attempting to disrupt or alter the relationship, contractual or otherwise, between the Company and any other person including, without limitation, any consultant, contractor, customer, potential customer, or supplier of the Company. He also agrees to maintain the confidentiality of all confidential or proprietary information of our company, and assign to us any inventions which pertain to or relate to our business or any of the work or businesses carried on by us that are discovered, conceived, reduced to practice, developed, made or produced by him during and as a result of his employment.

The employment agreement provides for payments and benefits upon termination of employment in addition to those previously accrued. If Mr. McCoy is terminated due to death, the salary payable to Mr. McCoy thereunder (in addition to items previously accrued, but excluding medical plan and other benefits) shall continue to be paid at the then current rate for three (3) months after the termination of employment in accordance with normal Company payroll practices. In addition, any bonuses actually earned prior to the termination (including, as reasonably determined by the Board of Directors or its Compensation Committee, a pro-rated amount of any annual bonus for the portion of the fiscal year during which termination takes place) shall be paid to Mr. McCoy.

In the event of the termination of Mr. McCoy’s employment due to disability, the salary payable there under (inclusive of paid medical plan then in effect and available, if any) shall continue to be paid at the then current rate for three (3) months after the termination of employment in accordance with normal Company payroll practices; provided, however, that the Company may deduct from such payments the amount of any and all disability insurance benefits paid during such three-month period with respect to Mr. McCoy that were paid for by the Company during any period for which payment was made by the Company during the term of the and prior to the termination. In addition, any bonuses actually earned prior to the termination (including, as reasonably determined by the Board of Directors or its Compensation Committee, a pro-rated amount of any annual bonus for the portion of the fiscal year during which termination takes place) which shall be paid to Mr. McCoy.

The table below summarizes all compensation awarded to, earned by, or paid to our officers for all services rendered in all capacities to us for our fiscal years ended September 30, ~~2020~~2022 and ~~2019~~2021.

SUMMARY COMPENSATION TABLE
Name and principal position	Year	Salary ($)		Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation ($)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)
Randall McCoy Chief Executive Officer, Principal Executive Officer and Director	~~2021~~2022 ~~2020~~2021	$250,0001) $250,000(2)		0 0	0 0	0 0	0 0	0 0	0 0	$250,000 $250,000
John J. Weber Chief Financial Officer and Director	~~2021~~2022 ~~2020~~2021	$125,000(5) $125,000(6)	0 0	0 0	0 0	0 0	0 0	0 0	$125,000 $125,000
Dr. J. Roy Nelson Chief Science Officer	~~2021~~2022 ~~2020~~2021	$150,000(3) $150,000(4)		0 0	0 0	0 0	0 0	0 0	0 0	$ 150,000 $150,000

	(1)	Of the $250,000 in salary to Mr. McCoy, $250,000 remains unpaid as accrued compensation.
	(2)	Of the $250,000 in salary to Mr. McCoy, $250,000 remains unpaid as accrued compensation.
	(3)	Of the $150,000 in salary to Mr. Nelson, $150,000 remains unpaid as accrued compensation.
	(4)	Of the $150,000 in salary to Mr. Nelson, $150,000 remains unpaid as accrued compensation.
	(5)	Of the $125,000 in salary to Mr. Weber, $125,000 remains unpaid as accrued compensation.
	(6)	Of the $125,000 in salary to Mr. Weber, $125,000 remains unpaid as accrued compensation.

Table of Contents

Outstanding Equity Awards at Fiscal Year-End

The table below summarizes all unexercised options, stock that has not vested, and equity incentive plan awards for each named executive officer as of September 30, ~~2020~~2022.

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
	OPTION AWARDS									STOCK AWARDS
Name	Number of Securities Underlying Unexercised Options (#) Exercisable		Number of Securities Underlying Unexercised Options (#) Unexercisable		Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)		Option Exercise Price ($)		Option Expiration Date (1)		Number of Shares or Units of Stock That Have Not Vested (#)		Market Value of Shares or Units of Stock That Have Not Vested ($)		Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)		Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (#)
Randall McCoy		885,672		—		—	$	0.035	12/31/23			—		—		—	—
John J. Weber		885,672		—		—	$	0.035	12/31/23			—		—		—	—
John J. Weber		10,000,000		—		—	$	0.02	12/31/23			—		—		—	—

(1) On December 31, 2018, the Board extended the term of the options to December 31, 2023.

Director Compensation

There has been no director compensation over the past three years.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth, as of January 6, 2020, certain information as to shares of our common stock owned by (i) each person known by us to beneficially own more than 5% of our outstanding common stock, (ii) each of our directors, and (iii) all of our executive officers and directors as a group.

Unless otherwise indicated below, to our knowledge, all persons listed below have sole voting and investment power with respect to their shares of Common Stock, except to the extent authority is shared by spouses under applicable law. Unless otherwise indicated below, each entity or person listed below maintains an address of 10 High Court, Little Falls, NJ 07424.

The number of shares beneficially owned by each stockholder is determined under rules promulgated by the SEC. The information is not necessarily indicative of beneficial ownership for any other purpose. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting or investment power and any shares as to which the individual or entity has the right to acquire beneficial ownership within 60 days through the exercise of any stock option, warrant or other right. The inclusion in the following table of those shares, however, does not constitute an admission that the named stockholder is a direct or indirect beneficial owner.

Beneficial owner	Number of shares beneficially owned ⁽¹⁾			Percentage Owned⁽²⁾
Officers and Directors
Randall McCoy		18,707,313	⁽³⁾		12.19	%
John J. Weber		10,935,672	⁽⁴⁾		7.12	%
Officers and Directors collectively		29,642,985			19.31	%
5 Percent Shareholders
Christopher Brown 100 N Tryon St. #4700 Charlotte, NC 28200		10,000,000			6.52	%

(1) Unless otherwise indicated, each person or entity named in the table has sole voting power and investment power (or shares that power with that person’s spouse) with respect to all shares of common stock listed as owned by that person or entity.

(2) A total of 162,333,050 shares of the Company’s common stock and Series A Convertible Preferred Stock, on an as converted basis, are considered to be outstanding pursuant to Rule 13d-3(d)(1) under the Securities Exchange Act of 1934.

(3) Includes 17,821,641 shares of common stock held in his name and options to purchase 885,672 shares of common stock.

(4) Includes 50,000 shares of common stock held in his name and options to purchase 10,885,672 shares of common stock.

Table of Contents

Other than the transactions described below and under the heading “Executive Compensation” (or with respect to which such information is omitted in accordance with SEC regulations), since October 1, 2012 there have not been, and there is not currently proposed, any transaction or series of similar transactions to which we were or will be a participant in which the amount involved exceeded or will exceed $120,000, and in which any director, executive officer, holder of 5% or more of any class of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest:

Our principal executive offices are located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Mr. McCoy. The office is attached to his residence but has its own entrances, restroom and kitchen facilities.

We also maintain an office in Pennington, New Jersey, which is the materials and testing laboratory. This office is owned by Materials Testing Laboratory, and the principal is an employee. In 2016, we entered into a supply agreement to supply collagen scaffolds from a company owned by the same employee.

We have an employment agreement with our CEO, Randall McCoy, as discussed above.

4. Randall McCoy, our Chief Executive Officer, made advances to us. The loans to not bear interest and are due on demand. At September 30, ~~2020~~2022 and ~~2019~~2021, the loan balance was $4,500 and $4,500, respectively.

5. John Weber, our Chief Financial Officer, made advances to us. The loans do bear interest at 5% per annum and are due on demand. At September 30, ~~2020~~2022 and ~~2019~~2021, the loan balance was $335,683 and $~~238~~335,~~133~~683 respectively.

Randall McCoy and John Weber were principals and partners in Pure Med Farma, a Limited Liability Company which we have engaged to provide our Closed Herd collagen, see discussion above.

7. Roy Nelson, our Chief Science Officer, made advances to us. The loans do not bear interest and are due on demand. At September 30, ~~2020~~2022 and ~~2019~~2021, the loan balance was $26,935 and $26,935, respectively.

Director Independence

We are not a “listed issuer” within the meaning of Item 407 of Regulation S-K and there are no applicable listing standards for determining the independence of our directors.

Item 14. Principal Accounting Fees and Services

We do not have an audit committee. Our Board of Directors pre-approves all services, including both audit and non-audit services, provided by our independent accountants. For audit services, each year the independent auditor provides our Board of Directors with an engagement letter outlining the scope of the audit services proposed to be performed during the year, which must be formally accepted by the Board of Directors before the audit commences. The independent auditor also submits an audit services fee proposal, which also must be approved by the Board of Directors before the audit commences.

We are filing this annual report without our auditors’ audit opinion of our financial statements for the years ended September 30, ~~2021~~2022 and ~~2020~~2021. Our reason for doing this is simply that we cannot afford at this time to pay our auditor for past due services on prior filings or to pay the costs necessary for this current filing. Instead, we have provided herein information as typically presented in our 10K annual report, including financial information, which has not been audited by any independent public accounting firm. Our auditor is N/A and their firm ID is 9999. The firm is located at N/A.

As a result, we have not included a schedule of audit fees related to fiscal years ended September 30, ~~2021~~2022 and ~~2020~~2021.

We intend, if and when able, to file an amendment to this 10K filing with such audited information. We are unaware at this time when, if ever, we will obtain the necessary funding for this amended filing, but we will continue to provide such information to investors as and when we are able through either this SEC EDGAR filing process and/or through postings on our website as things change.

Table of Contents

PART IV

Item 15. Exhibits, Financial Statements Schedules

(a)

Financial Statements and Schedules

The following financial statements and schedules listed below are included in this Form 10-K.

Financial Statements (See Item 8)

(b)

Exhibits

Exhibit Number	Description
3.1	Articles of Incorporation, as amended (1)
3.2	Bylaws, as amended (1)
3.3	Articles of Continuance
10.4	Know-How License and Stock Purchase Agreement (2)
10.5	Form of Stock Option Agreement(5)
10.6	Employment Agreement for Randall McCoy(4)
10.7	Asset Purchase Agreement(6)
14.1	Code of Ethics (3)
31.1	Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

	(1)	Incorporated by reference to the Registration Statement on Form SB-2 filed on October 22, 2006; also incorporated by reference to the Current Report on Form 8-K filed on October 29, 2010.
	(2)	Incorporated by reference to the Current Report on Form 8-K/A filed on April 27, 2011.
	(3)	Incorporated by reference to the Annual Report on Form 10-K filed on January 13, 2011.
	(4)	Incorporated by reference to the Current Report on Form 8-K filed on July 22, 2010.
	(5)	Incorporated by reference to the Current Report on Form 8-K filed on May 17, 2011.
	(6)	Incorporated by reference to the Current Report on Form 8-K filed November 17, 2014.

Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Regenicin, Inc.

By:	/s/ Randall McCoy
	Randall McCoy President, Chief Executive Officer, Principal Executive Officer, and Director
	January 13, 2022
	January 13, 2023

In accordance with Section 13 or 15(d) of the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

By:	/s/ Randall McCoy
	Randall McCoy President, Chief Executive Officer, Principal Executive Officer, and Director
	January 13, 2022
	January 13, 2023

By:	/s/ John J. Weber
	John J. Weber Interim Chief Financial Officer, Principal Financial and Accounting Officer, and Director
	January 13, 2022
	January 13, 2023

Table of Contents

Filing Compare · Regenicin, Inc.